SciSparc Ltd. (NASDAQ:SPRC) plunged 15.6% on Monday after announcing that it intends to purchase a portfolio of patents and intellectual property related to several endoscopic technologies — including the MUSE™ system — from Xylo Technologies Ltd.
The clinical-stage pharmaceutical company, acting through its majority-owned subsidiary NeuroThera Labs Inc., has entered into a binding term sheet to acquire Xylo’s patents, trademarks, and other IP covering advanced endoscopic platforms and medical imaging devices. Among them is the MUSE™ system, a disposable endoscopic device used to perform transoral fundoplication, a minimally invasive procedure for patients with gastroesophageal reflux disease (GERD).
As part of the agreement, SciSparc will issue ordinary shares equal to 19.99% of its current outstanding share count to Xylo once final agreements have been executed. The company also has the option to replace some or all of these shares with pre-funded warrants.
SciSparc hopes to emulate Xylo’s earlier commercial success in Greater China, where a licensing and distribution deal with a Shanghai-based medical device firm resulted in a $3 million upfront payment in 2019. The company intends to target similar commercial partnerships across North America, Europe, and Latin America.
Industry projections underscore the growth potential: market research from MarkNtel Advisors estimates the global GERD device sector was worth about $2.5 billion in 2024 and is on track to rise to $3.03 billion by 2030, reflecting a 3.24% CAGR from 2025 through 2030.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Some portions of this content may have been generated or assisted by artificial intelligence (AI) tools and been reviewed for accuracy and quality by our editorial team.
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.